Table 3.
Poisson regression of CBMN endpoints, lung cancer, and COPD, adjusted for age, sex, race, and smoking intensity
| Lung Cancer vs. aAll Controls | Relative Risk (95% Confidence Interval) |
|---|---|
| Micronuclei (BN-MN) | 1.95 (1.86–2.04) |
| Bridges (BN-NPB) | 4.36 (4.17–4.57) |
| Buds (BN-BUDS) | 1.79 (1.51–2.09) |
| Lung Cancer vs. bHealthy Controls | Relative Risk (95% Confidence Interval) |
| Micronuclei (BN-MN) | 1.98 (1.88–2.08) |
| Bridges (BN-NPB) | 4.44 (4.22–4.68) |
| Buds (BN-BUDS) | 1.95 (1.64–2.32) |
| COPD vs. bHealthy Controls | Relative Risk (95% Confidence Interval) |
| Micronuclei (BN-MN) | 1.05 (0.97–1.13) |
| Bridges (BN-NPB) | 1.05 (0.95–1.16) |
| Buds (BN-BUDS) | 1.29 (1.02–1.62) |
a
All controls include COPD participants
b
Healthy controls do not include COPD participants